Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review
Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard dose. The frequently observed adverse effects (AE) o...
Main Authors: | M. A. Gurianova, E. Yu. Chelysheva, O. A. Shukhov, A. G. Turkina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2020-09-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/43131/pdf |
Similar Items
-
Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy
by: A G Turkina, et al.
Published: (2017-12-01) -
Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)
by: EYu Chelysheva, et al.
Published: (2019-03-01) -
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01) -
First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
by: Chen KK, et al.
Published: (2018-09-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)